Most Read Articles
Saras Ramiya, 2 days ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Saras Ramiya, Yesterday
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

DOAC plus DAPT cuts risk of bleeding in AF patients with coronary disease

06 Oct 2018
The story of warfarin: From cattle killer to rat poison to humanity’s most cherished drug

Direct oral anticoagulants (DOACs) in combination with dual antiplatelet therapy (DAPT), compared with vitamin K antagonists (VKAs), correlate with a reduced risk of bleeding and similar thromboembolic protection in atrial fibrillation (AF) patients with myocardial infarction (MI) and/or after percutaneous coronary intervention (PCI), a recent study has shown.

Of the 3,222 patients included in the study, 875 (27 percent) were treated with VKA+single antiplatelet therapy (SAPT), 595 (18 percent) with DOAC+SAPT, 1,074 (33 percent) with VKA+DAPT and 678 (22 percent) with DOAC+DAPT.

A significant difference was observed at 3 months in the absolute risk of MI associated with DOAC+SAPT vs VKA+SAPT (3-month absolute risk difference [ARD], –1.53; 95 percent CI, –3.08 percent to –0.11 percent). There were no significant differences regarding bleeding, ischaemic stroke and all-cause mortality.

DOAC+DAPT correlated with a significantly reduced risk of bleeding (3-month ARD, –1.96; –3.46 percent to –0.88 percent) compared with VKA+DAPT, with no significant difference in the absolute risk of all-cause mortality, stroke or MI.

In this study, the investigators used Danish nationwide registries to identify AF patients who were admitted with a MI and/or underwent PCI, between August 2011 and June 2017, treated with oral anticoagulant in combination with antiplatelets (ie, aspirin, clopidogrel or both). They followed patients for 12 months or until an outcome, study end or death.

Based on outcome-specific Cox regression models adjusted for potential confounders, the investigators estimated standardized absolute risks. They used the g-formula to obtain average treatment effects as standardized ARD in risks at 3 and 12 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Saras Ramiya, 2 days ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Saras Ramiya, Yesterday
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).